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PET/CT in therapy control 
of infective native aortic aneurysms
Lars Husmann 1*, Martin W. Huellner1, Nadia Eberhard2, Bruno Ledergerber2, 
Marisa B. Kaelin2, Alexia Anagnostopoulos2, Ken Kudura1, Irene A. Burger1, 
Carlos‑A. Mestres3, Zoran Rancic4 & Barbara Hasse2
Infective native aortic aneurysms (INAA) are aneurysms arising from infection of the aortic wall. 
Treatment is demanding with 5‑year survival rates between 53 and 55%. The aim of our study was 
to evaluate the usefulness of 18F‑fluorodeoxyglucose positron emission tomography/computed 
tomography (PET/CT) in the long‑term monitoring of patients with proven INAA. Fifty‑three PET/
CT were performed in 15 patients with INAA in this single‑center retrospective cohort study and 
retrospective analysis of prospectively collected Vascular Graft Cohort Study (VASGRA) data. Median 
metabolic activity (as measured by maximum standardized uptake value, SUVmax) of the aneurysms 
at the initial PET/CT was high (6.8 (IQR 5.7–21.8)), and lower at the last PET/CT prior to the end of 
antimicrobial therapy (3.9 (IQR 2.7–6.8); n = 11) as well as in the first PET/CT after the end of the 
treatment (3.9 (IQR 3.0–4.4);n = 6). Compared to the course of C‑reactive protein alone, PET/CT 
provided different (> 20% difference in trend) or altering (opposed trend) information on the course 
of disease in at least 14 comparisons (56%) in 11 patients (73%). The one‑year and five‑year freedom 
from all‑cause lethality was 92% (95% confidence interval 57%‑99%). As compared to the course of 
C‑reactive protein, PET/CT provides different and occasionally altering information in therapy control 
of INAA.
Surgical and medical treatment of infective native aortic aneurysms (INAA) is demanding and the imminent 
rupture of the arterial vessel wall requires immediate surgical  care1,2. Open surgical treatment includes resection 
of the aneurysm, extensive local debridement, and revascularization by in situ reconstruction or extra-anatomic 
 bypass3,4. In recent years, there is increasing evidence that endovascular aortic repair (EVAR) of INAA may be 
an equivalent treatment  option5,6, especially in cases where the anatomic location of the aneurysm precludes 
open surgical repair. Endovascular treatment of INAA frequently leads to secondary vascular graft infections 
(VGI). Treatment of secondary graft infections generally involves long-term antimicrobial  therapy7,8 depend-
ing on the respective microorganisms, graft location, and involved graft material. Based on the heterogeneity 
of these factors, there are still many uncertainties with regard to the type and length of antimicrobial  therapy7.
18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) can be used to assess 
the treatment response in VGI. Its impact on patient management has been investigated in three preliminary 
 studies9–11, with promising results. To date, PET/CT has not been investigated in treatment response assessment 
of INAA. Thus, the aim of our study was to evaluate the usefulness of PET/CT in the long-term monitoring of 
patients with proven INAA.
Methods
Study design and definitions. Eligible participants included (a) prospectively acquired patients aged 
18  years or older with proven INAA and open and/or endovascular surgery enrolled in the Vascular Graft 
Cohort Study (VASGRA), or (b) retrospectively acquired patients with proven INAA, who were examined at 
least twice with PET/CT between the years 2005 and 2018. The study was approved by the local ethics com-
mittee, namely the Kantonale Ethikkomission Zürich (protocol number 2018-01904), and we obtained written 
informed consent from all participants who were either prospectively enrolled or examined between the years 
2016 and 2018; for subjects scanned between the years 2005 and 2015, written informed consent was waived due 
to retrospective inclusion by the local ethics committee, namely the Kantonale Ethikkomission Zürich (protocol 
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number 2018-01904). All procedures were performed in accordance with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards.
Diagnosis of INAA was made in an overall appraisal of clinical presentation (pain, fever, sepsis), laboratory 
(positive microbiological culture of aortic/aneurysmatic wall, presence of bacteria in thrombus or blood cul-
ture; elevation of inflammatory markers such as C-reactive protein and leucocytes) and  imaging5. Diagnosis of 
secondary VGI due to placement of stentgrafts relied on the MAGIC  criteria12.
In all prospectively enrolled patients, criteria for the termination of antimicrobial therapy were a combination 
of the absence of clinical features of infection, normal CRP, and reduced metabolic activity in PET/CT. Cure of 
INAA was defined as a combination of absence of clinical features, normal CRP, and reduced metabolic activ-
ity in PETCT at least three months after termination of antibiotic therapy (the latter only in the prospectively 
enrolled patients).
For retrospective inclusion of patients, we performed a retrospective chart review in all patients with sus-
pected INAA, who were examined with PET/CT between the years 2005 and 2018, if the term “mycotic aneu-
rysm”, “infective aneurysm”, or “infected aneurysm” was mentioned in the written PET/CT report, and was found 
to refer to an aneurysm of the thoracic, abdominal or pelvic arteries.
PET/CT examinations and patient follow‑up. The study design for all consecutively and prospectively 
enrolled patients included consecutive PET/CT scans, at baseline, during follow-up on antimicrobial therapy, 
and at the end of antimicrobial treatment. If feasible, a control PET/CT three months after the end of antimi-
crobial therapy was performed, to document continuous cure or possible signs for recurrence of infection. For 
all retrospectively enrolled patients, PET/CT was performed depending on the clinical situation of the patient; 
the reasons for patient’s referral are given in the results section. The exact time points of follow-up examinations 
with regard to the baseline are demonstrated in Fig. 1. For all patients, baseline was defined as first PET/CT scan 
at diagnosis of INAA.
We performed clinical follow-up of all patients by reviewing electronic patient charts. Patient data were 
recorded at the time of imaging, and at the last recorded clinical visit (recorded until March 2020).
Recorded data at baseline and at follow-up included patient demographics, clinical information, laboratory 
data (e.g. level of CRP and leucocyte count), results of microbiology, results from other diagnostic procedures, 
and information about treatment.
PET/CT data acquisition and image analysis. Five different types of PET/CT scanners were used 
within the study period between 2005 and 2018, i.e. a Discovery ST16, a Discovery VCT, two Discovery MI a 
Discovery 690 and a Discovery 710 (all GE Healthcare, Waukesha, WI). Body weight, height, and blood glucose 
level were measured prior to imaging (blood glucose levels < 12 mmol/l were  accepted13). All PET/CT examina-
tions followed basic study protocols: patients fasted for at least four hours, body-weight adjusted intravenous 
injection of  FDG14, standardized uptake time of 60 min in supine position, non-enhanced CT scans for attenu-
ation correction, data acquisition with arms overhead whenever possible.
All PET/CT examinations were independently analysed by two double board certified radiologists and nuclear 
medicine physicians, blinded to all clinical patient data. Readers determined the FDG uptake pattern in the 
aneurysm or graft to be focal or  diffuse15. A consensus reading was performed if results differed. Furthermore, 
both readers quantified the FDG-uptake in the aneurysm or in the vascular graft by measuring the maximum 
standardized uptake value (SUVmax) in the aneurysm or graft as well as in the liver and mediastinal bloodpool 
(the latter as background for reference). In case SUVmax measurements were not identical among both readers 
concerning the measurements in the aneurysm or graft, a consensus reading was performed; in case of discordant 
SUVmax values for the background measurements, the mean was calculated. To compensate for differences in the 
sensitivity of the different PET/CT scanner generations between the years 2005 and 2018, and resulting differ-
ences in quantitative PET parameters (i.e. SUVmax), we calculated relatively scanner-independent FDG uptake 
ratios (i.e. SUVratio was defined as uptake in the aneurysm of graft in relation to the mediastinal blood pool). 
To determine differences between the course of C-reactive protein and SUVratio we calculated trends between 
consecutive examinations, and defined an arbitrary cut-off of > 20% between differences in trends as relevant.
Furthermore, for all baseline and follow-up PET/CT examinations, readers determined whether a INAA or a 
VGI was present or not, using a visual 4-point grading score. Score 1 (no signs for infected aortic aneurysm/VGI) 
and score 2 (most likely a non-infected aneurysm/VGI) were considered negative for infected aortic aneurysm, 
while score 3 (suspicion of infected aortic aneurysm/VGI) and score 4 (clear signs of infected aortic aneurysm/
VGI) were considered positive for infection.
Statistical analyses. Variables were expressed as median and interquartile range (25th, 75th percentiles) 
or percentages. Kaplan–Meier estimates were used to describe survival at 1 and 5 years. We compared sizes and 
visual grading scores of INAA from initial and last CT scans using nonparametric pairwise Wilcoxon signed-
rank test. Mixed-effects multilevel linear regression were applied to analyze the individual changes of SUVmax, 
SUVratio and CRP. Statistical analysis were performed using commercially available software (Stata/SE, Version 
15.1, StataCorp, College Station, Texas).
Results
Patient population. Seven out of 21 (33%) patients with confirmed INAA were prospectively enrolled, 
while 14 (66%) patients were retrospectively included. Five out of 14 retrospective patients were excluded due to 
lack of written consent and one out of the seven prospective patients was excluded due to lack of clinical follow-
up after the first PET/CT.
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Thus, the final patient population consisted of 15 patients. All patients were eventually treated with open 
and/or endovascular repair (six prior to the first PET/CT, seven prior to the second, and two prior to the third 
PET/CT) (Table 1).
At the time of the initial PET/CT examination, patients had a median age of 61 years (IQR 54–85), one patient 
(7%) was female, six (40%) were smokers or had a history of smoking, two (13%) patients were diabetic, and six 
(40%) had renal insufficiency. The diagnoses of INAA were confirmed by blood culture (n = 11; 73%), culture or 
PCR from tissue obtained during surgical revision (n = 2; 13%) and serology (n = 2, 13%) (Table 2).
PET/CT examinations. We performed a total of 53 PET/CT scans in 15 patients (Figs. 1, 2, 3, Table 3) after 
intravenous injection of a median of 353 Megabecquerel of FDG (IQR 334—400). Initial imaging was per-
formed for nine (60%) patients before and for six (40%) patients after vascular intervention, 11 (73%) received 
antimicrobial therapy at the time of initial imaging. The median visual 4-point grading score was 4 (11 × score 4, 
3 × score 3, 1 × score 2). Eventually, all patients underwent vascular intervention with graft placement, and were 
treated with antibiotics (Tables 1 and 2). All aneurysms (or grafts) had increased focal FDG uptake on the initial 
PET/CT examination (SUVmax 6.8 (IQR 5.7–21.8); SUVmax aneurysm/graft to blood pool background ratio 
2.7 (IQR 2.2–7.3)). FDG uptake in all aneurysms/grafts (100%) was higher than liver background (SUVmax 3.4 
(IQR 2.7–6.1) (Figs. 1, 2, 3, Table 3).
The first follow-up PET/CT (112 (IQR 95–721) days after the first PET/CT) was performed in all patients, and 
13 (87%) patients received antimicrobial therapy at the time (in one patient antimicrobial therapy was started 
after the second PET/CT in another therapy was already terminated). The median visual 4-point grading score 
Figure 1.  Courses over time of metabolic activity in PET/CT (SUVmax and SUVratio in the two graphs on 
the left) and CRP (graph on the right) in patients with proven infective native aortic aneurysms. Note: PET/CT 
provides additional or altering information (as defined in the methods section) on the course of disease in at 
least 14 comparisons (56%) in 11 patients (73%), as compared to CRP alone (i.e. patients: 02, 03, 04, 05, 06, 07, 
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decreased to 3 (3 × score 4, 8 × score 3, 2 × score 2, 2 × score 1). The first follow-up showed an overall decrease in 
SUVmax (5.5 (IQR 3.0–8.2) and SUVmax ratio (2.2 (IQR 1.6–2.9)); SUVmax decreased in 13 and increased in 
two patients, SUVmax ratio decreased in 10 and increased in five patients (Figs. 1, 2, 3, Table 3).
In 11 patients, PET/CT was performed prior to the termination of the antimicrobial therapy. Compared to 
background activity, PET/CT showed focally increased FDG uptake in nine patients (82%) and diffuse increased 
FDG uptake in two patients (18%) with SUVmax 3.9 (IQR 2.7–6.8) and SUV ratio 1.7 (IQR 1.2–2.9). The FDG 
uptake in the aneurysm/graft was higher than blood pool background in eight (73%) patients (Fig. 2) and higher 
than liver background in seven (64%) patients. The median CRP was 12.0 mg/L (IQR 3–218). Of note, the median 
time difference between the last PET/CT prior to the termination of antimicrobial therapy and the actual end of 
antimicrobial therapy was a median 30 days (IQR 18–1059), and six examinations (55%) were considered to be 
directly linked to the decision to end treatment.
A total of eight PET/CT were performed after termination of the antimicrobial therapy treatment in six 
patients (SUVmax in all eight PET/CT: 4.2 (IQR 3.3–4.7); SUVmax in the first six PET/CT 3.9 (IQR 3.0–4.4). 
Compared to background activity, six (75%) of these examinations showed increased and focal FDG uptake 
(SUVmax 4.2 (IQR 3.3–4.7), SUV ratio 1.7 (IQR 1.5–4.1)), in two examinations (25%) the uptake was considered 
diffuse; FDG uptake was higher than blood pool background (SUVmax 2.2 (IQR 2.0–2.9)) and liver background 
(SUVmax 3.2 (IQR 2.7–3.6)) in all examinations (100%). The median visual 4-point grading score after termina-
tion of the antimicrobial therapy was 3 (0 × score 4, 5 × score 3, 2 × score 2, 1 × score 1).
The comparison of the last PET/CT prior to the termination of antimicrobial therapy to the first PET/CT after 
termination of antimicrobial therapy (feasible in six patients) showed less focal FDG-uptake (from five to four) 
Table 1.  Patient demographics, data on interventional procedures, and patient outcome data of the final study 
population in patients with proven infective native aortic aneurysms. Pat: Patient number; na, not applicable. 
*Patient died due to gastrointestinal bleeding, no relation to thoracic INAA. † Patient developed 1.5 years 
later an infected pancreatic cyst. ‡ The active intravenous drug user died 8 years later due to aortic valve 
endocarditis.
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and decreasing FDG uptake in three patients for SUVmax and in two patients for SUVratio, while the uptake 
increased in three patients for SUVmax and in four patients for SUVratio (SUVmax from 3.8 to 3.9 (IQR 2.5–4.4 
and 3.0–4.4) and SUV ratio from 1.6 to 1.7 (IQR 0.9–1.9 and 1.5–4.1)). Notably, the two patients with a signifi-
cantly rising SUV ratio (from 0.7 to 2.0 and from 0.7 to 1.2; patient 9 and 13 in Table 3) had no signs of infection 
at the last clinical follow-up, which was more than five and more than eight years after the last PET/CT and 
without antimicrobial therapy. None of these patients had clinical signs of new VGI at the last clinical follow-up.
Sizes of INAA, measured on CT images, decreased significantly by 1.45 cm on average from the initial to the 
last examination (p = 0.016, Table 3). In parallel, visual grading scores for INAA decreased by 1.2 on average 
(p < 0.01, Table 3).
Discrepancies between trends of SUVratio and CRP. With 53 PET/CT performed in 15 patients we 
were able to calculate 38 trends of SUVratio and 25 trends of CRP (immediate data of CRP missing for 13 PET/
CT).
The decrease or increase of SUVratio was paralleled by decreasing or increasing CRP values in 16 of 25 (64%) 
trends, while it was opposed in nine (36%) examinations. Nineteen comparisons (76%) showed either opposed 
trends (as mentioned above, n = 9) and/or differences between trends of CRP and SUVratio > 20%. For these 
trends, PET/CT provided a conclusive explanation for the difference in five comparisons (26%) in three patients 
(i.e. additional foci of infection with different response to therapy: patient 05, 11, and 14 in Table 3 and Fig. 2). No 
apparent reason for high differences in trend could be determined for four comparisons (21%) in four patients 
(i.e. three opposed trends between first and second PET/CT in patient 04, 07, and 11 (Table 3) and a high 46% 
increase in CRP paralleled by a low 11% increase of SUVratio in patient 09 in Table 3). In five comparisons of 
five patients, CRP values showed very good or complete responses to therapy at the time of the first follow-up 
PET/CT, which were paralleled by less pronounced partial responses in SUVratio (patient 02, 03, 06, 08, and 
15); further clinical follow-up could not determine which methods better described the actual clinical response 
to therapy (as all other clinical parameters defining cure of INAA were normal/unchanged). The final five com-
parisons of differences between trends of CRP and SUVratio which were > 20%, were rated to be errors as the 
values were very low and partly normal, i.e. between the fourth and fifth PET/CT of patient 02 (Table 3), CRP 
values decreased by 80% from 2.1 to 1.3, which was paralleled by a 20% increase in SUV ratio from 1.65 to 1.84.
Hence, PET/CT provided additional or altering information on the course of disease in at least 14 compari-
sons (56%) in 11 patients (73%), as compared to CRP alone.
Patient outcome. Patients were clinically followed for a median of 1496 days (IQR 961–3187 days) after 
their initial PET/CT examination and for a median of 1005 days (IQR 683–3109 days) after their last PET/CT 
Table 2.  Data on microbiology and antimicrobial of the final study population in patients with proven 
infective native aortic aneurysms. Pat: Patient number; na, not applicable. *Microbiology resulted from blood 
culture (n = 11), culture or PCR from tissue obtained during surgical revision (n = 2) and serology (n = 2).
Pat Microbiology*
Antimicrobial treatment
Intravenous Oral Strategy Duration (days) Complications
01 Escherichia coli Piperacillin/tacobactam Ciprofloxacin Prolonged 136 None
02 Streptococcus agalactiae Cetriaxone Amoxicillin/clavulanic acid Prolonged 382 None
03 Candida albicans Caspofungin Fluconazol Prolonged 192 None
04 Streptococcus agalactiae Penicillin Clindamycin Prolonged 289 Port infection
05 Streptococcus agalactiae Ceftriaxone Clindamycin Prolonged 220 None































Clindamycin Prolonged 118 None




13 Salmonella typhi Ceftriaxon Ciprofloxacin Prolonged 99 None




Lifelong Infinite Allergy to doxycyclin
15 Porphyromonas gingivalis Penicillin Clindamycin Prolonged 1139 None
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examination. The one-year and five-year freedom from all-cause mortality was 92% (95% confidence interval 
[CI] 57–99%), for both. Overall mortality was 3.5% (0.9–13.8) per year. Two events occurred in 57.8 years of 
Figure 2.  PET/CT of an 82-year old male patient (patient 05 in Tables 1, 2 and 3) with a vascular graft 
infection and spondylodiscitis due to Streptococcus agalactiae showed a new focal FDG uptake in the wall of 
the thoracic aorta in September 2017. Both readers rated the thoracic finding as a infective native aneurysm 
despite the fact that the vessel diameter was not pathologically widened. The first PET/CT follow-up in revealed 
a progression of the aneurysm in size with stable increased FDG uptake; at the same time the FDG uptake of 
the spondylodiscitis increased while it partially decreased in the vascular graft infection; C-reactive protein 
and white blood cell count decreased. After subsequent thoracic endovascular repair with an Endurant II Stent 
Graft Systems (MEDTRONIC), two further PET/CT follow-up, before and after termination of antimicrobial 
therapy (223 days of therapy) showed faint residual FDG uptake in all sites of infection. At the last clinical 
follow-up in January 2019 the patient was in good clinical condition with no sign of infection. Note: Panels A-D 
show maximum intensity reconstructions of PET; Panels E-P show fused PET/CT images. Abbreviations: PET: 
positron emission tomography; CT: computed tomography; FDG: 18F-fluorodeoxyglucose.
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follow-up time; i.e. two patients (13%) died because of reasons considered unlikely to be related to INAA; one 
died due to gastrointestinal bleeding (location of the INAA was in the aortic arch), the other due to aortic valve 
endocarditis (after more than six years after successful treatment of the INAA).
The two patients (13%) on continuous antibiotic therapy, showed higher metabolic activity in the INAA 
(SUVmax 7.9 and 4.7, SUVratio 2.4 and 1.6) than the mean metabolic activity of those patients that were scanned 
prior to the termination of antimicrobial treatment (as mentioned above: SUVmax 3.9 (IQR 2.7–6.8) and SUV 
Figure 3.  A 70-year old male patient (patient 04 in Tables 1, 2 and 3) presented with chest pain and signs for 
infection (C-reactive protein 122 mg/L). The initial PET/CT examination showed strongly increased FDG-
uptake in the wall of an aortic arch aneurysm and no other infectious foci. Both PET/CT readers suspected a 
infective native aneurysm; which was clinically confirmed (Streptococcus agalactiae in blood cultures). At first 
PET/CT follow-up (ongoing antimicrobial therapy, after thoracic endovascular repair with a Conformable 
GORE TAG Thoracic Endoprosthesis and debranching) a strong residual focal FDG-uptake was detected 
adjacent to the graft, in line with a secondary vascular graft infection. The second PET/CT follow-up (ongoing 
antimicrobial therapy), showed only very faintly increased FDG-uptake adjacent to the graft. However, a new 
pneumonia in the right lower lobe was incidentally detected. The patient died 60 days after the last PET/CT 
due to a gastrointestinal bleeding not related to the thoracic infective native aortic aneurysm. Note: Panels A-C 
show maximum intensity reconstructions of PET; Panels D-I show fused PET/CT images. Abbreviations: PET: 
positron emission tomography; CT: computed tomography; FDG: 18F-fluorodeoxyglucose.
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Table 3.  Patient demographics, follow-up PET/CT and CT findings of the final study population in patients 
with proven infective native aortic aneurysms. Pat: Patient number; AB: antimicrobial treatment; n.a.: not 
applicable; stranding: fat stranding; fluid: fluid collection; CE: contrast enhancement, gas: gas formation; 
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ratio 1.7 (IQR 1.2–2.9)). The conditions of these two patients were determined to be stable at the last clinical 
visit 261, and 729 days after the last performed PET/CT.
One patient (7%) showed recurrent signs of infection at the last clinical visit, which were attributed to an 
infected pancreatic cyst. All other patients (n = 10, 67%) did not show any signs of infection at the last clinical 
visit and all were without antimicrobial therapy (Table 1).
Among patients alive without antimicrobial therapy, yearly changes of SUVmax, SUVratio and CRP were 
-3.5 (95% CI -5.5 to -1.5, p < 0.01), -1.0 (-1.7 to -0.3, p < 0.01) and -58 (-96 to -20, p < 0.01), respectively. Among 
patients still on antimicrobial therapy or who died, yearly changes of SUVmax, SUVratio and CRP were -0.39 
(95% CI -0.81 to 0.03, p = 0.07), -0.20 (-0.33 to -0.08, p < 0.01) and -4.6 (-14.2 to 5.1, p = 0.35), respectively.
Discussion
To the best of out knowledge, this is the first study investigating the role of PET/CT in therapy control of INAA. 
Our study results show: (i) PET/CT adds additional information in therapy control of INAA. (ii) Metabolic 
activity in the aneurysms remains slightly elevated after the end of antimicrobial therapy and therefore should 
not be mistaken for persistent infection.
All patients of the present study were treated with open and/or endovascular repair, and as this treatment in 
INAA frequently leads to secondary graft infections, we may compare the present study results to the findings of 
three previous  publications9–11 on therapy control with PET/CT in VGI. In line with these  studies9–11, we found 
that in addition to laboratory and clinical information, consecutive PET/CT examinations were a valuable source 
of information for treatment monitoring, often displaying additional and sometimes even opposed results to 
clinical and laboratory parameters.
Previous studies have documented a correlation between the course of CRP and SUVmax in therapy control 
of patients with  VGI10. In the present study, only a minority of comparisons (i.e. 24%) of CRP and the metabolic 
activity in the aneurysm showed a similar course in therapy control of patients with INAA. The majority of cases 
displayed large discrepancies between trends of CRP and metabolic activity or even opposed courses. The latter, 
may partly be explained by additional foci of infection with different response to therapy, which was in line with 
results of a previous study, showing correlation between CRP and SUVmax only in a subpopulation of patients 
with VGI without additional infectious  foci9.
However, we could identify another group of comparisons with no apparent reason for the large discrepan-
cies between trends of CRP and metabolic activity, which may indicate, that CRP and metabolic activity in the 
aneurysm are two unrelated identities, which may have to be evaluated independently, when treating patients 
with INAA. Because of such discrepancies and the overall severity of INAA in general, we believe that in all 
patients with INAA, decisions for further therapy should always be based also on other parameters such as 
clinical aspects (general health status, fever, clinical signs of INAA and/or graft infection), and other laboratory 
parameters (CRP, ESR, leucocytes).
Furthermore, we documented in line with previous  reports16–18, that the metabolic activity in INAA is initially 
high or very high, and comparable to the initial presentation of VGI in PET/CT9–11,15,19–25. Under antimicrobial 
therapy the metabolic activity generally  decreases9–11. However, the metabolic activity remains above background 
level before and even after the end of medical treatment; despite the fact that we did not observe any cases of 
recurrent infection. High rates of residual metabolic activity were also observed in patient populations with VGI 
at the end of medical treatment. Husmann et al.10 observed a complete metabolic response to treatment in only 
33% of patients with VGI, while we could not observe a complete response in any of our patients. The reason 
for this difference remains unclear, and may possibly be due to differences in the course of two similar but yet 
different diseases, or it may be due to bias as our study cohort was considerably smaller in number. Notably, 
residual metabolic activity (i.e. SUVmax values slightly above background level) in the aneurysms after the end 
of medical treatment should not be mistaken for persistence of infection in INAA, but may possibly represent a 
sterile ongoing inflammatory reaction, as none of our patients showed signs of recurrence during the follow-up 
of this series and an excellent patient outcome was observed.
Two patients died due to reasons not considered unrelated to INAA. The one-year and five-year freedom from 
all-cause mortality was 93%, and was much higher than in previously published studies, which found five-year 
survival rates between 53%26 and 55%7. Whether disease monitoring with PET/CT contributed to the excellent 
clinical outcome in the present study still remains unanswered. However, we could not find any other obvious 
systematic difference, which may account for the improved clinical outcome.
Limitations of the study. The present study population is heterogeneous, with varying numbers of fol-
low-up PET/CT examinations, as well as prospectively and retrospectively included patients, which precludes 
standardized PET/CT intervals. Furthermore, due to the lack of comparable data in the literature, we defined an 
arbitrary cut-off of > 20% between differences in trends of SUVratio and CRP as relevant.
Despite these limitations, the results of the present study appear consequential and should be confirmed in 
further studies.
Conclusion
As compared to the course of C-reactive protein, PET/CT provides different and occasionally altering information 
in therapy control of INAA. Of note, metabolic activity in the aneurysms remains slightly elevated even after the 
end of antimicrobial therapy and should not be mistaken for persistent infection.
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